Alzheimer’s disease (AD) affects 50–70% of patients with dementia, making it the leading cause of dementia. The condition is classified as a neurodegenerative, progressive and incurable disease. The disease is affecting more and more people around the world. AD has a multifactorial nature, spreading from beta-amyloid deposition to inflammation in patients’ brains. Patients experience cognitive impairment and functional decline. Although it is a disease that occurs mainly in the elderly, it is increasingly being diagnosed in young people between the ages of 30 and 40. It not only affects the patient themself but also reduces the quality of life of their closest caregivers. According to the WHO, the treatment of AD consumes USD 1.3 trillion globally, but it is only symptomatic, as there are no drugs to prevent the onset of AD or treat the cause of its onset. Due to the numerous side effects of therapy and the lack of proactive drugs that act on the pathomechanism of AD, alternative therapies are being sought. One possible option that has many studies confirming its effect is phytotherapy. Many herbs have pharmacological properties, such as antioxidant, anti-inflammatory, or neuroprotective effects, making them the future of cognitive disorders and AD treatment. This review focuses on some of the most promising herbs that have potentially potent properties and effects in AD therapy. These include Curcuma longa, Panax ginseng, Berberis and Crocus sativus. These herbs may perhaps be key in the future to make functioning and life easier for patients struggling with AD.

Introduction and objective: Civilization diseases are widespread in the adult population. However, their occurrence has been increasing recently in children. The aim of this review is to introduce the most common diseases and present their diagnosis and treatment methods. Review methods: The...

Introduction and objective: Drug-resistant epilepsy (DRE) is a serious therapeutic challenge, as approximately 30% of epileptic patients do not achieve sustained seizure control despite using at least two appropriately selected antiepileptic drugs. Although pharmacotherapy is the basis of...

Introduction and objective: Tourette syndrome is a neuropsychiatric disorder that begins in childhood and reaches its peak just before adolescence. The disorder is severely troublesome for patients not only by the motor and phonic tics that occur, but also by the often co-occurring behavioural...

Background: Bronchiolitis, a common lung infection in infants, is mainly caused by RSV. Supportive treatment seems adequate in the majority of children. According to some recommendations, treatment with bronchodilators may be attempted, which can be administered, among others, using a metered-dose inhaler (MDI) in combination with valved holding chamber. Objective: To assess whether neonates can generate sufficient inspiratory flow to open the one-way (inspiratory) valve of VHC. Methods: The study included 20 newborns, aged 21-28 days, hospitalized for RSV bronchiolitis. They were born at 38-40 weeks gestation, weighed 3000-3500g, scored at least 8 on the Apgar scale, and had no congenital malformations. Newborns' ability to open the VHC inspiratory valve three times in 10 seconds was assessed by measuring pressure in the spacer using a respiratory pressure meter (MicroRPM, Vyaire Medical, USA), which was connected to the inner chamber of VHC (AeroChamber Plus Flow-Vu, Trudell Medical International, London) through a 15 cm long silicone tube. The VHC was equipped with a fitted face mask and a drug-free MDI. The measurement was performed before starting treatment in an awake child. Results: The mean age of participants was 25 days and the mean weight was 3925g. 11 children (55%) generated a pressure in the chamber at least three times in 10 seconds, so were capable to obtained sufficient inspiratory flow to open the inspiratory valve of VHC. Conclusion: Every other newborn with bronchiolitis, aged 21-28 days is unable to generate inspiratory flow that will allow the one-way valve in the VHC to open and, therefore, take the drug from the spacer. Therefore, nebulization seems to be preferable.